Opinion|Videos|January 31, 2025
Partnering With Patient Advocacy Groups to Improve HS Awareness and Outcomes
Author(s)Hadar Lev-Tov, MD
Panelist discusses how patient advocacy groups act as critical bridges between patients, researchers, and health care providers, ultimately improving recognition, treatment, and quality of life for individuals affected by hidradenitis suppurativa.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Can you discuss the role of patient advocacy groups in promoting early recognition and comprehensive care for HS?
- Closing thoughts on HS for the AJMC viewing audience.
Advertisement
Related to this article
October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.
Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.
From taladegib to admilparant and inhaled treprostinil, here are the key 2026 advances in idiopathic pulmonary fibrosis care.
HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.
Real-world data show antifibrotic dose reductions in IPF were not significantly linked to faster disease progression vs staying on full dose.
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
As Employers Pull Back on GLP-1s, Andel and Novo Offer a Workaround
3
Birth Weight, Childhood Weight Gain Linked to Non-Hodgkin Lymphoma Risk
4
Kidney Week 2026 Recap: IgAN Advances, Value-Based Care, CKD Care Gaps
5